

MINUTES

Genetic Modification Safety Committee Meeting
1st December 2022, 10:30-10:50am
MS Teams – Online Meeting



Attendees present:

Khwaja Islam (KI) (Chair, BioEscalator Biological Safety Officer)
Graham Ross (GR) (University Divisional Safety Officer)
Len Seymour (LS) (Professor of Genetic Therapy, Bioescalator Management Board Member)
John Sinclair (JS) (Chief Technical Officer, The Protein Forge)
Catarina Oliveira (CO) (Lab Operations Manager, Alethiomics)
Graham McClorey (GM) (Director of Biology, Orfonyx Bio)
Amy Hall (AH) (Lab Operations Manager, Exogene)
Christian Willberg (CW) (Head of Research, MediMab Therapeutics)
Lian Ni Lee (LL) (Vice-President Pre-Clinical Development, Infinitopes)
Piotr Jedryszek (PJ) (Director, Evolvere)
Ying Hung (Minutes)

Apologies:

Kevin Maskell (Research Director, Bioarchitech)
Adam Winniffrith (Director, Evolvere)

1. Welcome and introduction

- a. KI welcomed attendees.

2. Minutes of the last meeting:

- a. Minutes of the last meeting held 29th November 2021 approved by committee members. No amendments to be made.

3. Matters arising:

3.1 New company and departures

- a. KI introduce new members and companies: AH, Exogene; CO, Alethiomics; JS, The Protein Forge; GM, Orfonyx Bio.
- b. Company departure- Ochre Bio, Nucleome Therapeutics, Cyanocapture and Theraport.

3.2 Approval of Risk Assessments (RA) prior to the meeting.

- a. Alethiomics- Class 1 and Class 2
- b. Evolvere- Class 1

The next Genetic Modification Safety Committee Meeting is Nov/ Dec 2023

MINUTES

Genetic Modification Safety Committee Meeting

1st December 2022, 10:30-10:50am

MS Teams – Online Meeting



- c. Protein Forge- Class 1
- d. Orfonyx Bio- Class 1
- e. KI informed the attendees when the license has been approved, it can be used in other buildings.

3.3 Turnaround on RA once submitted to committee to review

- a. KI reminded the attendees there are template available for RA, it is the company duty to appoint a Safety Representative to sign their own RA. As BioEscalator Safety Officer, he is not allowed to sign the company RA. The company has to submit the RA to the committee for review, and then submit the HSE application themselves.
- b. CO mentioned the turnaround time is around 2 weeks and is reasonable.
- c. LL mentioned it took around 6 weeks for HSE Class 1 application, longer time for Class 2 application.
- d. GM mentioned the HSE invoice came quickly.
- e. All agreed 2 weeks is a reasonable turnaround for both sides- the company and the committee to review RA.
- f. LS mentioned some submitted RA provided insufficient information to review due to the confidentiality issue. He suggested that the committee will send the enquiries to KI, and then KI address to the company.
- g. CO mentioned Alethiomics stated the reason why they did not provide the confidential details during the HSC application, they will come back with enquiries and the company can explain further.

4. AOB

- a. GR reminded the attendees RA is part of the public record. Company should have in mind what to keep internally and externally.

5. Date and venue of next meeting

- a. November/ December 2023

The next Genetic Modification Safety Committee Meeting is Nov/ Dec 2023